DRREDDY Dr. Reddy's Laboratories Q4 FY26 results (Jan–Mar 2026) and concall
Dr. Reddy's Laboratories reported a resilient FY26 with highest-ever annual revenues, despite product-specific headwinds and one-time impacts like a ₹453 crore lenalidomide shelf stock adjustment. The underlying base business achieved double-digit growth, and the company made significant progress on key pipeline assets like semaglutide and abatacept, securing regulatory approvals and BLA acceptance. While Q4 margins were impacted by product mix and impairments, management expects improvement to above 50% in FY27, maintaining an adjusted EBITDA margin of approximately 25% for the full year.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue down 31.3%, net profit down 118.2% against the same quarter last year.
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 5,015 | 5,563 | 7,810 | 4,619 | 4,283 −15% | 3,822 −31% |
| EBITDA | 1,192 | 1,443 | 3,837 | 480 | 100 −92% | -500 −135% |
| Net profit | 849 | 1,201 | 2,961 | 387 | 91 −89% | -219 −118% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
